Our findings, particularly the association between elevated TIGAR expression and poorer survival rates in HCC patients, as well as the correlation between TIGAR and humoral immunity, have significantly expanded our understanding of the molecular landscape of HCC. This evidence concerns the gene TIGAR and hepatocellular carcinoma.